 |
2016-01-28 12:40:15 It's OK best price ●●●●●●e foam ●●●●●● There ●●●●●●s ample ●●●●●●unity to ●●●●●●e the ●●●●●●ing ●●●●●● over the ●●●●●● term by ●●●●●●ing ●●●●●●er sales ●●●●●● and ●●●●●●ging it ●●●●●●t a ●●●●●●vely fixed ●●●●●●e base. Other ●●●●●●es, net of $15 ●●●●●●n in the ●●●●●●r, were up ●●●●●●ly from last year and we ●●●●●●ue to ●●●●●●st other ●●●●●●es at about $58 ●●●●●●n for the full year. The ●●●●●●ive tax rate was 34.2% in the ●●●●●● ●●●●●●r, and we ●●●●●●ue to ●●●●●●te a 35% rate for the full year. Adding it all ●●●●●●er, net ●●●●●●gs ●●●●●●sed 16% in the ●●●●●● ●●●●●●r and ●●●●●●d EPS rose 15%, which was ●●●●●●●●●●●● ●●●●●● than our ●●●●●●us ●●●●●●sted ●●●●●●gs equal to last year. Three ●●●●●● ago, we had ●●●●●●d our sales ●●●●●● ●●●●●●ation for the full year due to a ●●●●●●●●●●●●g ●●●●●●mance in the A●●●●●●s, as well as to ●●●●●● in a ●●●●●● yen. At this point, we are ●●●●●●ining a ●●●●●●us sales ●●●●●●k for the A●●●●●●s until we see solid ●●●●●●ce of an ●●●●●●. Our ●●●●●●tions call for full year ●●●●●●ide sales to grow by a mid-●●●●●● digit ●●●●●●tage in ●●●●●●s and by a high-●●●●●● digit in local ●●●●●●cy. With local ●●●●●●cy comp ●●●●●● ●●●●●●g from high-●●●●●● ●●●●●● in Asia-P●●●●●● and Japan to low-●●●●●● ●●●●●● in the A●●●●●●s. buy ●●●●●●c ●●●●●● drug The ●●●●●●-door ●●●●●●g ●●●●●●ed ●●●●●●r ●●●●●●e ●●●●●●n onT●●●●●● ●●●●●●n top Obama ●●●●●●●●●●●●on ●●●●●●als, ●●●●●●●●●●●●yists and ●●●●●●y ●●●●●●tes, P●●●●●●o ●●●●●●ed, ●●●●●● ●●●●●●e ●●●●●● ●●●●●●g "was ●●●●●●zed with ●●●●●●r ●●●●●●y." |